Vimarsana
Biggest News Aggregation in the World

Page 3 - Aim Leukemia News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Aim Leukemia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Aim Leukemia Today - Breaking & Trending Today

FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID - Vimarsana News

FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID

/PRNewswire/ -- Curis, Inc., (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule triple...

Curis Announces $15.1 Million Registered Direct Offering - Vimarsana News

Curis Announces $15.1 Million Registered Direct Offering

/PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, a triple target inhibitor (IRAK4, FLT3 and CLK)...

FDA Lifts Partial Clinical Hold on TakeAim Leukemia Trial of Emavusertib in AML/MDS - Vimarsana News

FDA Lifts Partial Clinical Hold on TakeAim Leukemia Trial of Emavusertib in AML/MDS

The FDA has lifted a partial clinical hold on the phase 1/2 TakeAim Leukemia trial evaluating emavusertib monotherapy and in combination with azacitidine and venetoclax in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome.

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Vimarsana News

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

Curis Provides First Quarter 2023 Business Update - Vimarsana News

Curis Provides First Quarter 2023 Business Update

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...